

Study: ENGOT-ov82 / EvoPAR-Ovo1

Rechallenge with PARPi in 1st platinum sensitive relapse for patients who received PARPi in 1st line but did not progressed under PARPi therapy.

MaNGO Sites

Prov	City	Site	Principal Investigator	Active **
AL	Alessandria	Ospedale SS Antonio e Biagio	Giulia Gallizzi	
FI	Firenze	Ospedale Careggi	Maria Cristina Petrella	
MI	Milano	Istituto Europeo di Oncologia	Nicoletta Colombo	
TO	Torino	Ospedale Sant'Anna	Elisa Piovano*	

* MaNGO Principal Investigator

** MaNGO sites list to be confirmed by Sponsor